P Andreone
Overview
Explore the profile of P Andreone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
1032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conti F, Serra C, Andreone P
Clin Gastroenterol Hepatol
. 2020 Nov;
19(3):619.
PMID: 33248100
No abstract available.
2.
Mazzaro C, Dal Maso L, Visentini M, Gitto S, Andreone P, Toffolutti F, et al.
J Intern Med
. 2019 May;
286(3):290-298.
PMID: 31124596
Cryoglobulinemic vasculitis (CV) can develop in 1.2-4% of hepatitis B virus (HBV)-infected patients. HBV infection affects about 350 million people worldwide. It can progress from acute or fulminant hepatitis to...
3.
Pettinari I, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C, et al.
Am J Gastroenterol
. 2018 Dec;
114(2):258-266.
PMID: 30538290
Objectives: Portal vein thrombosis (PVT) is a frequent complication of cirrhosis. Benefit, safety, and duration of anticoagulant treatment in this setting are controversial issues. The aim of this study was...
4.
Agarwal K, Ahn S, Elkhashab M, Lau A, Gaggar A, Bulusu A, et al.
J Viral Hepat
. 2018 Jun;
25(11):1331-1340.
PMID: 29851204
Vesatolimod is an oral agonist of toll-like receptor 7 designed to minimize systemic exposure and side effects. We assessed the safety and efficacy of vesatolimod in viremic chronic hepatitis B...
5.
Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, et al.
Aliment Pharmacol Ther
. 2018 May;
47(12):1705-1712.
PMID: 29722439
Background: The efficacy of direct-acting anti-viral (DAA) therapy in patients with a history of hepatocellular carcinoma (HCC) is unknown. Aim: We prospectively evaluated whether previously treated HCC affects DAA efficacy...
6.
Vukotic R, Conti F, Fagiuoli S, Morelli M, Pasulo L, Colpani M, et al.
J Viral Hepat
. 2017 Apr;
24(10):858-864.
PMID: 28370880
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence....
7.
Gelsomino F, Vitale G, DErrico A, Bertuzzi C, Andreone P, Ardizzoni A
Ann Oncol
. 2016 Dec;
28(3):671-672.
PMID: 27993797
No abstract available.
8.
Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli M, Lalanne C, et al.
J Viral Hepat
. 2016 Dec;
24(6):454-463.
PMID: 27976461
The availability of direct-acting antiviral agents (DAA) regimens has expanded the pool of patients eligible for treatment. However, data on the virologic response and tolerability of DAAs in elderly patients...
9.
Vukotic R, Di Donato R, Conti F, Scuteri A, Serra C, Andreone P
J Viral Hepat
. 2016 Dec;
24(1):13-16.
PMID: 27905669
During the past two decades, several studies showed reduced rates of hepatocellular carcinoma recurrence in patients with HCV-related cirrhosis after interferon-based antiviral therapies respect to untreated controls, even without reaching...
10.
Gamal N, Andreone P
Drugs Today (Barc)
. 2016 Aug;
52(7):377-85.
PMID: 27540596
Hepatitis C virus (HCV) infection is an increasing public health concern with an estimated 184 million people infected worldwide and approximately 350,000 deaths yearly from HCV-related complications. There is a...